Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06774027 · ClinicalTrials.gov registry record
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
A clinical trial of Metastatic Breast Cancer and HER2-Negative Breast Cancer, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06774027 is a study of Metastatic Breast Cancer and HER2-Negative Breast Cancer that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 100 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06774027, a study of Metastatic Breast Cancer and HER2-Negative Breast Cancer, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC), offering an effective new treatment strategy. Several outstanding questions drive the decision to use ADC drugs clinically. This is a prospective, multi-site observational study of patients with metastatic breast cancer (mBC) who are being treated with FDA-approved antibody drug conjugates (ADCs) as part of routine care and aims to collect real-world data to evaluate the impact of ADC treatment as part of routine care.
Conditions Studied
Interventions
- OTHER Medical Record Review
- PROCEDURE Specimen collection
- DRUG Non-Investigational Antibody-Drug Conjugates (ADC)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2030-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06774027
The ClinicalTrials.gov registry entry for NCT06774027 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (51% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Medical Record Review is the first listed.
NCT06774027 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06774027 about?
NCT06774027 is a clinical study titled "Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer". Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone receptor positive/HER2 negative (HR+/HER2-) metastatic bre...
What is the current status of trial NCT06774027?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-10-08. Estimated completion is 2030-12-31.
What conditions does trial NCT06774027 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, HER2-Negative Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, HER2-Negative Breast Carcinoma, HR+ HER2- Breast Cancer.
What interventions are being tested in trial NCT06774027?
The interventions under investigation include: Medical Record Review (OTHER), Specimen collection (PROCEDURE), Non-Investigational Antibody-Drug Conjugates (ADC) (DRUG).
Who is sponsoring clinical trial NCT06774027?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06774027 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.